Mylan gets one step closer to finally challenging Glaxo's Advair

Generic competition to GlaxoSmithKline ($GSK) respiratory behemoth Advair could finally be on the horizon, and Mylan ($MYL) wants to make sure it gets a piece of the med's blockbuster revenues. On Friday, the company announced that the FDA had accepted its application for a copy of the blockbuster, with a decision date set for March 28, 2017. Mylan joins Hikma and Novartis' ($NVS) Sandoz, which have already made FDA submissions. Release

Suggested Articles

A self-proclaimed former employee at Novartis’ Beijing office accused the Swiss drugmaker of expensing fake academic events to offer kickbacks to doctors.

Novo Nordisk just won an FDA approval that could help it stand out in the crowded—and competitive—basal insulin category.

Pfizer is training pharmacists in the U.K. to handle over-the-counter Viagra.